⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL181346 | 0.74 | — | — | |
| SCHEMBL2479932 | 0.71 | — | — | |
| SCHEMBL30978372 | 0.70 | — | — | |
| Ammonia Solution, Strong SCHEMBL30978376 | 0.70 | — | — | |
| Hydrochloric Acid SCHEMBL27868973 | 0.70 | — | — | |
| Hydrogen Sulfide SCHEMBL28797397 | 0.70 | — | — | |
| SCHEMBL27938586 | 0.70 | — | — | |
| SCHEMBL15522455 | 0.65 | — | — | |
| SCHEMBL4077 | 0.64 | — | — | |
| SCHEMBL626538 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3022199-A1 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2016-05-25 | — | — | EP | claimed |
| WO-2015008872-A1 | CYANOTRIAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-01-22 | — | — | WO | claimed |
| CN-109195965-B | Inhibitors of WDR5 protein-protein binding | 普罗佩纶治疗公司 | 2022-07-26 | — | — | CN | disclosed |
| US-20150335624-A1 | COMPOSITIONS AND METHODS FOR USING HUPERZINE AND ANALOGS THEREOF | INSERO HEALTH INC (US) | 2015-11-26 | — | — | US | disclosed |
| US-20150191430-A1 | CONJUGATES OF HUPERZINE AND ANALOGS THEREOF | BISCAYNE NEUROTHERAPEUTICS, INC. | 2015-07-09 | — | — | US | disclosed |
| US-20130296226-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF METABOLIC DISORDERS | HALIMED PHARMACEUTICALS INC (US) | 2013-11-07 | — | — | US | disclosed |
| WO-2013166468-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | INSERO HEALTH INC. (US) | 2013-11-07 | — | — | WO | disclosed |
| US-8476221-B2 | Methods and compositions for the treatment of metabolic disorders | HALIMED PHARMACEUTICALS, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-20120238490-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF METABOLIC DISORDERS | HALIMED PHARMACEUTICALS, INC. | 2012-09-20 | — | — | US | disclosed |
| US-20120142601-A1 | Modified Peptides and Uses Thereof | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT | 2012-06-07 | — | — | US | disclosed |
| EP-1773310-B9 | ALPHA, BETA-UNSATURATED SULFONES, SULFOXIDES, SULFONIMIDES, SULFINIMIDES, ACYLSULFONAMIDES AND ACYLSULFINAMIDES AND THERAPEUTIC USES THEREOF | UNIV TEMPLE (US) | 2012-04-25 | — | — | EP | disclosed |
| EP-0882701-B1 | SUBSTITUTED AMIDE DERIVATIVES | BANYU PHARMA CO LTD (JP) | 2002-07-24 | — | — | EP | disclosed |
| EP-1165515-A1 | PYRIDINE-2,3-DICARBOXYLIC ACID DIAMIDES | BASF AKTIENGESELLSCHAFT (DE) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000058288-A1 | PYRIDINE-2,3-DICARBOXYLIC ACID DIAMIDES | BASF AKTIENGESELLSCHAFT (DE) | 2000-10-05 | — | — | WO | disclosed |
| US-6048894-A | FARNESYL-PROTEIN TRANSFERASE INHIBITORS, ANTITUMOR OR ANTICANCER AGENTS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2000-04-11 | — | — | US | disclosed |
| US-6011174-A | INHIBIT PROTEIN-FARNESYL TRANSFERASE (PFT) IN VIVO THEREBY TO SUPPRESS FUNCTION OF ONCOGENE PROTEIN RAS AND THUS PRESENT ANTITUMOR ACTIVITIES, | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2000-01-04 | — | — | US | disclosed |
| EP-0882703-A1 | CYCLIC AMIC ACID DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1998-12-09 | — | — | EP | disclosed |
| EP-0882701-A1 | SUBSTITUTED AMIDE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1998-12-09 | — | — | EP | disclosed |
| US-5597776-A | ANTAGONIST FOR HERBICIDES | BASF AKTIENGESELLSCHAFT (DE) | 1997-01-28 | — | — | US | disclosed |
| EP-0537463-A2 | Substituted pyrido(2,3-d)pyrimidines as antidotes | BASF Aktiengesellschaft (DE) | 1993-04-21 | — | — | EP | disclosed |